ClinicalTrials.gg
RecruitingNCT06581432Updated Nov 10, 2026

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

A Phase 2 interventional study of Zongertinib in Solid Tumours, sponsored by Boehringer Ingelheim. Recruiting at 93 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 10, 2026Site recruiting status changedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
588
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2.

Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it.

Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

02

Conditions studied

  • Solid Tumours
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥18 years
  • Documented Human epidermal growth factor receptor 2 ()-positive status or known activating HER2 mutations (by local testing)
  • or cytologically confirmed locally advanced, unresectable, or solid tumours
  • Disease progression following prior treatment in the metastatic setting (including treatment with antibody-drug conjugates (ADCs)) and no suitable standard of care treatment options
  • Availability of sample to confirm HER2 status
  • Presence of ≥1 outside the central nervous system (CNS) according to (RECIST) v1.1 (investigator assessed)
  • (ECOG) performance status of 0 or 1 Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  • Diagnosis of -positive (overexpressed/amplified) breast cancer
  • Diagnosis of HER2-mutant non-small cell lung cancer (NSCLC)
  • Previous treatment with any HER2 tyrosine kinase inhibitors (TKIs)
  • Previous or concomitant other than the one treated in this trial within the previous 3 years except the following effectively treated cancers: nonmelanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, localized prostate cancer on watchful waiting or active surveillance, and other effectively treated malignancies that are considered cured by local treatment
  • Uncontrolled or symptomatic brain or subdural metastases during screening
  • Known diagnosis of
  • Intake of restricted medications or any drug considered likely to interfere with the trial being conducted in a safe mannerFurther exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
588 participants (estimated)

Study arms

  • Experimental
    Zongertinib treatment

    Drug: Zongertinib

Interventions

  • Zongertinib

    Also known as: BI 1810631, Hernexeos®

06

What researchers measure

Primary outcomes

  1. Proportion of patients with objective response (OR)

    according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 by central independent review, and it will be summarised descriptively as absolute and relative frequencies

    Time frame: Up to 51 months

Secondary outcomes

  1. Duration of objective response (DOR)

    Duration of objective response (DOR) is defined as the time from first documented Objective response (OR) according to RECIST 1.1 until the earliest date of disease progression or death among patients with confirmed OR, assessed by central independent review.

    Time frame: Up to 51 months

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from treatment start until the earliest date of tumour progression according to RECIST 1.1 assessed by central independent review, or death from any cause, whichever occurs first.

    Time frame: Up to 51 months

  3. Disease control (DC)

    Disease control (DC) is defined as best overall response (BOR) of complete response (CR) or partial response (PR) or stable disease (SD) where BOR is defined according to RECIST 1.1 from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before the start of subsequent anti-cancer therapy, or treatment discontinuation, as assessed by central independent review.

    Time frame: Up to 51 months

  4. Occurrence of treatment-emergent Adverse Events (AEs)

    Time frame: Up to 51 months

  5. Change from baseline to Week 48 or progressive disease (PD) by central independent review, if earlier, of the EORTC QLQ-C30, which includes IL-19, the physical functioning scale

    QLQ-C30 incorporates both multi-items scales and single-item measures. These include 1 global health status/QoL scale, 5 functional scales, 3 symptoms scales and 6 single items to assess dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. European Organisation for Research and Treatment of Cancer, quality-of-life questionnaire (EORTC QLQ-C30) does not produce a single overall summary score by default. Scores can be reported via domain-specific scores or summary score (since 2016) ranging from 0 to 100 with higher scores representing a better QoL.

    Time frame: At baseline and up to 48 weeks

  6. Overall survival (OS)

    OR is defined as the time from start of treatment to death from any cause

    Time frame: Up to 51 months

07

Study locations

81 of 93 sites recruiting
08

References and documents

Publications

  • Schram AM, Park JJ, Italiano A, Kitano S, Guo Y, Li J, Bedard PL, van Marcke C, Ko R, Lunger L, Klotz DM, Hussain J, Maier D, Erzen D, Planchard D, Prenen H, Clay TD, Park JO, Kim HD, Hernando-Calvo A, Maruki Y, Ponz-Sarvise M, Dumbrava E. Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol. 2026 Mar;22(7):795-803. doi: 10.1080/14796694.2026.2637740. Epub 2026 Mar 4. PubMed 41777164 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link hhttps://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Nov 2028, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Oct 11, 2024
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 29, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 3 sites removed. 6 sites changed recruiting status (4 now recruiting, 2 now completed)
Show 6 sites
  • CTR Leon Berard · Lyon, FranceRecruiting→Completed
  • Fondazione Policlinico Universitario Campus Bio-medico · Rome, ItalyNot yet recruiting→Recruiting
  • Universitätsklinikum Mannheim GmbH · Mannheim, GermanyRecruiting→Completed
  • Okayama University Hospital · Okayama, Okayama, JapanNot yet recruiting→Recruiting
  • Hospital Duran i Reynals · Barcelona, SpainNot yet recruiting→Recruiting
  • Centro di riferimento Oncologico · Aviano (PN), ItalyNot yet recruiting→Recruiting
Show 4 added (2 United Kingdom, 1 United States, 1 Spain)
  • BRCR Global - Tamarac · Tamarac, United States
  • The Christie · Manchester, United Kingdom
  • Hospital Universitario Virgen del Rocio · Seville, Spain
  • Queen Elizabeth Hospital Birmingham · Birmingham, United Kingdom
Show 3 removed
  • BRCR Global · Tamarac, United States
  • The Christie Hospital · Manchester, United Kingdom
  • Hospital Virgen del Rocio · Seville, Spain
across 5 updates, Sep 29, 2026 – Nov 10, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedDiagnosis of HER2-positive (overexpressed/amplified) metastatic breast cancer or metastatic gastroesophageal adenocarcinoma
Oct 20, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • GenesisCare North Shore · St Leonards, AustraliaContact added a•••@bitrialsupport.com · •••1035
  • CTR Leon Berard · Lyon, FranceContact removed f•••@bitrialsupport.com · •••2354
  • Universitätsklinikum Mannheim GmbH · Mannheim, GermanyContact removed d•••@bitrialsupport.com · •••4742
across 2 updates, Sep 29, 2026 – Oct 13, 2026
Show all 5 updates
  1. Nov 10, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Spain, 1 United Kingdom)
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    • Queen Elizabeth Hospital Birmingham · Birmingham, United Kingdom
    Show 1 removed
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Oct 28, 2026
    Centro di riferimento Oncologico is now Recruiting
  3. Oct 20, 2026
    1 site added, 1 site removed. Hospital Duran i Reynals is now Recruiting
    Show site
    • The Christie · Manchester, United Kingdom
    Show 1 removed
    • The Christie Hospital · Manchester, United Kingdom
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedDiagnosis of HER2-positive (overexpressed/amplified) metastatic breast cancer or metastatic gastroesophageal adenocarcinoma
  4. Oct 13, 2026
    2 sites changed recruiting status (1 now completed, 1 now recruiting)
    Show 2 sites
    • Universitätsklinikum Mannheim GmbH · Mannheim, GermanyRecruiting→Completed
    • Okayama University Hospital · Okayama, Okayama, JapanNot yet recruiting→Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Universitätsklinikum Mannheim GmbH · Mannheim, GermanyContact removed d•••@bitrialsupport.com · •••4742
    + 1 other change: verification date
  5. Sep 29, 2026
    1 site added, 1 site removed. 2 sites changed recruiting status (1 now completed, 1 now recruiting)
    Show 2 sites
    • CTR Leon Berard · Lyon, FranceRecruiting→Completed
    • Fondazione Policlinico Universitario Campus Bio-medico · Rome, ItalyNot yet recruiting→Recruiting
    Show site
    • BRCR Global - Tamarac · Tamarac, United States
    Show 1 removed
    • BRCR Global · Tamarac, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • GenesisCare North Shore · St Leonards, AustraliaContact added a•••@bitrialsupport.com · •••1035
    • CTR Leon Berard · Lyon, FranceContact removed f•••@bitrialsupport.com · •••2354

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06581432
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Oct 11, 2024
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zongertinib

Start the discussion